← Leaderboards
Kevin R Flaherty
University Of Michigan At Ann Arbor
$9,330,908
Attributed
$17,924,351
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,924,351 · 8
By mechanism
RC2$7,915,507 · 1
U24$6,632,877 · 1
R01$1,560,062 · 1
K24$908,780 · 1
K23$667,475 · 1
M01$137,374 · 2
Top collaborators
- Catherine A Spino6 shared
- Fernando J Martinez2 shared
- Galen B Toews1 shared
- Eric S White1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Catherine A Spino$34,285,809
- George J Brewer$2,763,501
- Sofia Diana Merajver$3,387,621
- Susan G. Urba$225,204
- Xudong Fan$6,206,272
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisClinical TrialsLungResearch PersonnelDatabasesData CollectionClinical ResearchTrainingProtocols DocumentationInterstitial Lung DiseasesDesignSamplingMichiganMethodologyProspectiveHamman-Rich SyndromeMeetingsUniversitiesBiometryResearch DesignOutcome ForecastPlayCessation Of LifeCollaborations
Grant awards (27)
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$408,088
U24 · FY2025 · HL
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$627,206
U24 · FY2024 · HL
Short Term Biomedical Research Training Program for Students$102,276
T35 · FY2024 · HL · contact PI
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,346,213
U24 · FY2023 · HL
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,793,103
U24 · FY2022 · HL
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,875,962
U24 · FY2021 · HL
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$582,305
U24 · FY2019 · HL
Forging a road to personalized medicine in interstitial lung diseases$181,756
K24 · FY2017 · HL · contact PI
Forging a road to personalized medicine in interstitial lung diseases$181,756
K24 · FY2016 · HL · contact PI
Forging a road to personalized medicine in interstitial lung diseases$181,756
K24 · FY2014 · HL · contact PI
Forging a road to personalized medicine in interstitial lung diseases$181,756
K24 · FY2013 · HL · contact PI
Forging a road to personalized medicine in interstitial lung diseases$181,756
K24 · FY2012 · HL · contact PI
Longitudinal, computer assisted analysis in IPF$384,431
R01 · FY2011 · HL · contact PI
CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis$3,695,556
RC2 · FY2010 · HL
Longitudinal, computer assisted analysis in IPF$384,483
R01 · FY2010 · HL · contact PI
CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis$4,219,951
RC2 · FY2009 · HL
Longitudinal, computer assisted analysis in IPF$384,535
R01 · FY2009 · HL · contact PI
Longitudinal, computer assisted analysis in IPF$406,613
R01 · FY2008 · HL · contact PI
PHASE I/II TRIAL TETRATHIOMOLYBDATE (TM) IN PTS W/ USUAL INTERSTITIAL PNEUMONIA$453
M01 · FY2007 · RR · contact PI
Prognostication In Idiopathic Interstitial Pneumonia$133,623
K23 · FY2006 · HL · contact PI
PHASE I/II TRIAL TETRATHIOMOLYBDATE (TM) IN PTS W/ USUAL INTERSTITIAL PNEUMONIA$25,549
M01 · FY2006 · RR · contact PI
Prognostication In Idiopathic Interstitial Pneumonia$133,623
K23 · FY2005 · HL
PHASE I/II TRIAL TETRATHIOMOLYBDATE (TM) IN PTS W/ USUAL INTERSTITIAL PNEUMONIA$86,974
M01 · FY2005 · RR
Prognostication In Idiopathic Interstitial Pneumonia$133,623
K23 · FY2004 · HL
Phase I/II Trial Tetrathiomolybdate (TM) in Pts w/ Usual Interstitial Pneumonia$24,398
M01 · FY2004 · RR
Prognostication In Idiopathic Interstitial Pneumonia$133,623
K23 · FY2003 · HL
Prognostication In Idiopathic Interstitial Pneumonia$132,983
K23 · FY2002 · HL